Host-pathogen systems for early drug discovery against tuberculosis

Area of Science:

• Microbiology
• Drug Discovery
• Infectious Diseases

Background:

• Tuberculosis (TB) remains a significant global health threat, causing millions of deaths annually.
• The rise of drug-resistant Mycobacterium tuberculosis strains necessitates novel anti-mycobacterial agents.
• Current drug discovery pipelines struggle to keep pace with emerging drug resistance.

Purpose of the Study:

• To review current screening methodologies for anti-mycobacterial compounds.
• To highlight the importance of incorporating in vivo properties into drug screening.
• To explore alternative host-pathogen systems for enhanced drug discovery.

Main Methods:

• Review of existing literature on TB drug screening.
• Analysis of whole cell-based screening approaches.
• Evaluation of zebrafish larvae models for TB drug discovery.
• Assessment of artificial granuloma research in anti-mycobacterial compound characterization.

Main Results:

• Current screening methods often lack in vivo relevance.
• Novel host-pathogen systems offer improved efficacy in identifying anti-mycobacterial compounds.
• Alternative systems like zebrafish larvae and artificial granulomas show promise.

Conclusions:

• Optimized screening procedures incorporating host-pathogen systems are crucial for TB drug discovery.
• Exploring underutilized host-pathogen models can accelerate the development of new anti-TB drugs.
• Integrating in vivo characteristics into early screening improves the identification of effective anti-mycobacterial therapies.